NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Shareholders who purchased shares of ATNM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/actinium-loss-submission-form/?id=147113&from=3  CLASS PERIOD: October ...

Core Insights - Actinium Pharmaceuticals is advancing Iomab-ACT, a targeted radiotherapy conditioning agent intended to replace traditional chemotherapy agents for CAR-T therapy, with initial clinical data expected in the second half of 2025 [1][2][3] - The Iomab-ACT trial aims to improve patient access and outcomes by reducing CAR-T related toxicities such as ICANS and CRS, which are significant barriers for patients [2][3] - The CAR-T therapy market generated over $4 billion in sales in 2024 and is projected to reach $12 billion by 2030, indicating a substantial market opportunity for Iomab-ACT [1][5] Company Developments - The first patient has been enrolled in the Iomab-ACT trial at the University of Texas Southwestern Medical Center, marking a significant step in the development of this innovative therapy [1][2] - Iomab-ACT targets CD45, selectively depleting immune cells associated with CAR-T toxicities while sparing essential blood components, which could lead to better patient outcomes [2][3] - Initial clinical results from a pilot study showed no patients developed ICANS and minimal CRS, supporting the advancement of Iomab-ACT into commercial trials [2][3] Market Opportunity - The addressable market for Iomab-ACT aligns with the approximately 150,000 patients annually who require conditioning for CAR-T therapies, suggesting a potential blockbuster revenue opportunity if clinical benefits are demonstrated [5] - The pipeline of CAR-T therapies is rapidly expanding, with the patient population expected to nearly double by 2030, further enhancing the market potential for Iomab-ACT [5]

NEW YORK, May 6, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were adversely affected by alleged securities fraud between October 31, 2022 and August 2, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/actinium-lawsuit-subm ...

Core Viewpoint - A class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. for misleading investors regarding the approval prospects of its Biologics License Application for lomab-B, leading to significant stock price decline [1][4]. Group 1: Lawsuit Details - The class action lawsuit is filed in the U.S. District Court for the Southern District of New York on behalf of investors who acquired Actinium securities from October 31, 2022, to August 2, 2024 [1]. - Investors have until May 27, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Regulatory Update - On August 5, 2024, Actinium announced that the FDA determined the data from its Sierra trial did not support a BLA filing for lomab-B, necessitating an additional clinical study [3]. - Following this announcement, Actinium's share price fell by $3.69, or approximately 59%, from $6.17 on August 2, 2024, to $2.48 on August 5, 2025 [3]. Group 3: Allegations - The complaint alleges that during the Class Period, Actinium misled the market into believing that the data submitted for its BLA would meet FDA guidelines for acceptance and approval [4].

NEW YORK, May 5, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM).Shareholders who purchased shares of ATNM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/actinium-loss-submission-form/?id=146601&from=4CLASS PERIOD: October 31, 2022 ...

NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were adversely affected by alleged securities fraud between October 31, 2022 and August 2, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/actinium-lawsu ...

NEW YORK, May 2, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were adversely affected by alleged securities fraud between October 31, 2022 and August 2, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/actinium-lawsuit-subm ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Actinium Pharmaceuticals, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's Iomab-B BLA application and its clinical trial data [2][4]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses exceeding $75,000 in Actinium between October 31, 2022, and August 2, 2024, to discuss their legal rights [1]. - A federal securities class action has been filed against Actinium, with a deadline of May 26, 2025, for investors to seek the role of lead plaintiff [2][6]. Group 2: Allegations Against Actinium - The complaint alleges that Actinium and its executives made false and misleading statements regarding the likelihood of FDA approval for the Iomab-B BLA, based on data from the Sierra Trial [4]. - It is claimed that the additional analyses provided to the FDA were unlikely to satisfy the agency's guidelines, leading to a probable refusal to review or approve the BLA [4]. Group 3: Impact on Stock Price - Following the revelation of the need for an additional clinical trial to support the BLA filing, Actinium's stock price dropped significantly, falling $3.69, or nearly 60%, to close at $2.48 on August 5, 2024 [5].

NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Shareholders who purchased shares of ATNM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/actinium-loss-submission-form/?id=146179&from=3 CLASS PERIOD: October ...

NEW YORK, May 1, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM).Shareholders who purchased shares of ATNM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/actinium-loss-submission-form/?id=146165&from=4CLASS PERIOD: October 31, 2022 ...